Wednesday, November 7, 2012

Novartis KK files QVA149 for approval in Japan

Novartis Pharma K.K. has submitted an application for the registration of QVA149, an investigational fixed dose combination of two long-acting inhaled bronchodilators (indacaterol maleate andglycopyrronium bromide), as a once-daily treatment for chronic obstructive pulmonary disease (COPD) in Japan.

Enter your email address:


Delivered by FeedBurner